Abstract
Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Keywords: Receptor, channel, patch clamp, kinetics
Current Neuropharmacology
Title: Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids
Volume: 8 Issue: 1
Author(s): Gustav Akk, Douglas F. Covey, Alex S. Evers, Steven Mennerick, Charles F. Zorumski and Joe Henry Steinbach
Affiliation:
Keywords: Receptor, channel, patch clamp, kinetics
Abstract: Endogenous neurosteroids and synthetic neuroactive steroid analogs are among the most potent and efficacious potentiators of the mammalian GABA-A receptor. The compounds interact with one or more sites on the receptor leading to an increase in the channel open probability through a set of changes in the open and closed time distributions. The endogenous neurosteroid allopregnanolone potentiates the α1β2γ2L GABA-A receptor by enhancing the mean duration and prevalence of the longest-lived open time component and by reducing the prevalence of the longest-lived intracluster closed time component. Thus the channel mean open time is increased and the mean closed time duration is decreased, resulting in potentiation of channel function. Some of the other previously characterized neurosteroids and steroid analogs act through similar mechanisms while others affect a subset of these parameters. The steroids modulate the GABA-A receptor through interactions with the membrane-spanning region of the receptor. However, the number of binding sites that mediate the actions of steroids is unclear. We discuss data supporting the notions of a single site vs. multiple sites mediating the potentiating actions of steroids.
Export Options
About this article
Cite this article as:
Akk Gustav, Covey F. Douglas, Evers S. Alex, Mennerick Steven, Zorumski F. Charles and Steinbach Henry Joe, Kinetic and Structural Determinants for GABA-A Receptor Potentiation by Neuroactive Steroids, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909458
DOI https://dx.doi.org/10.2174/157015910790909458 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Short-Term Educational and Behavioral Therapy on Childhood Obesity
Vascular Disease Prevention (Discontinued) Agonist-Regulated Internalization and Desensitization of the Human Nociceptin Receptor Expressed in CHO Cells
Current Drug Targets New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Inferring Alcoholism SNPs and Regulatory Chemical Compounds Based on Ensemble Bayesian Network
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: Innate Immune Responses in CNS Neurodegenerative Diseases (Guest Editors: Hans van Noort and Sandra Amor)]
CNS & Neurological Disorders - Drug Targets Nutraceuticals and their Derived Nano-Formulations for the Prevention and Treatment of Alzheimer's Disease
Current Molecular Pharmacology Anthocyanins As Modulators of Cell Redox-Dependent Pathways in Non-Communicable Diseases
Current Medicinal Chemistry Design and Synthesis of Benzopyranopyrimidinyl Phosphonates as Cytotoxic and Antioxidant Agents
Letters in Drug Design & Discovery Role of the Central Cholinergic System in the Therapeutics of Schizophrenia
Current Neuropharmacology Lead Encephalopathy Due to Traditional Medicines
Current Drug Safety Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology Intracranial Aneurysms in Sickle Cell Disease
Current Neurovascular Research The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment
Current Medicinal Chemistry Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry Innovative Models for the Empowerment of Patients with Type 2 Diabetes: The CAIPaDi Program
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Embryonic Morphogenetic Field Induces Phenotypic Reversion in Cancer Cells. Review Article
Current Pharmaceutical Biotechnology Crosstalk Between the Autophagy-Lysosome Pathway and the Ubiquitin-Proteasome Pathway in Retinal Pigment Epithelial Cells
Current Molecular Medicine Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Elevated Plasma Level of D-dimer Predicts the High Risk of Early Cognitive Impairment in Type 2 Diabetic Patients as Carotid Artery Plaques become Vulnerable or Get Aggravated
Current Alzheimer Research New Proposals for Treatment Sporadic Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry